Goekbuget, Nicola and Zugmaier, Gerhard and Dombret, Herve and Stein, Anthony and Bonifacio, Massimiliano and Graux, Carlos and Faul, Christoph and Brueggemann, Monika and Taylor, Kate and Mergen, Noemi and Reichle, Albrecht and Horst, Heinz-August and Havelange, Violaine and Topp, Max S. and Bargou, Ralf C. (2020) Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 61 (11). pp. 2665-2673. ISSN 1042-8194, 1029-2403
Full text not available from this repository. (Request a copy)Abstract
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE(R)immuno-oncotherapy, 15 mu g/m(2)/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59 center dot 8 months, median survival (months) was 36 center dot 5 (95% CI: 22.0-not reached [NR]). Median survival was NR (29.5-NR) for complete MRD responders (n = 84) and 14.4 (3.8-32.3) for MRD non-responders (n = 23;p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7-NR) (n = 61) and 16.5 (1.1-NR) (n = 10;p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STANDARD-RISK; TRANSPLANTATION; MRD; QUANTIFICATION; REMISSION; THERAPY; RELAPSE; BLOOD; Acute lymphoblastic leukemia; minimal residual disease; allogeneic hematopoietic stem cell transplantation; blinatumomab; immuno-oncotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2021 09:46 |
| Last Modified: | 19 Mar 2021 09:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44306 |
Actions (login required)
 |
View Item |
